Management and Prevention of Atopic Dermatitis Infectious Complications in Children
Roman V. Epishev,
Alexander I. Materikin,
Leonid A. Opryatin,
Roman A. Ivanov,
Maria A. Leonova,
Alena A. Savelova https://doi.org/10.15690/vsp.v22i5.2638
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease with high risk of skin and systemic infections. Preventive AD therapy is based on skin barrier improvement and anti-inflammatory treatment, whereas, severe skin and systemic infections require systemic therapy. This review describes pathophysiology and possible treatment and prevention methods for AD infectious complications.
Supporting agencies: The article was published with the financial support of Pierre Fabre LLC
About the Authors
Roman V. Epishev
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen, Pfizer, Celgene. Receiving fees for scientific counseling from company Mölnlycke Health Care AB
Alexander I. Materikin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen, Pfizer, Celgene. Receiving fees for scientific counseling from company Mölnlycke Health Care AB
Leonid A. Opryatin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving fees for scientific counseling from companies Eli Lilly, Jansen
Roman A. Ivanov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Maria A. Leonova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Alena A. Savelova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
References
1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/S01406736(20)31286-1
2. Emelyashenkov EE, Sviridova TV, Murashkin NN, et al. Psychological readiness of parents of young children with atopic dermatitis to implement medical recommendations. Russian Pediatric Journal. 2023;26(1):46–53. (In Russ). doi: https://doi.org/10.46563/1560-9561-2023-26-1-46-53
3. Ali F, Vyas J, Finlay AY. Counting the Burden: Atopic Dermatitis and Health-related Quality of Life. Acta Derm Venereol. 2020;100(12): adv00161. doi: https://doi.org/10.2340/00015555-3511
4. Edslev SM, Agner T, Andersen PS. Skin Microbiome in Atopic Dermatitis. Acta Derm Venereol. 2020;100(12):adv00164. doi: https://doi.org/10.2340/00015555-3514
5. Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan, and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018;120(1):66–72.e11. https://doi.org/10.1016/j.anai.2017.10.019
6. Wang V, Keefer M, Ong PY. Antibiotic choice and methicillinresistant Staphylococcus aureus rate in children hospitalized for atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(3):314–317. doi: https://doi.org/10.1016/j.anai.2018.12.001
7. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 Suppl 1:8–16. doi: https://doi.org/10.1159/000370220
8. Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: https://doi.org/10.1038/s41572-018-0001-z
9. Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi: https://doi.org/10.1111/bjd.16934
10. Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52. doi: https://doi.org/10.1186/s13223-018-0281-6
11. Elias PM, Sugarman J. Does moisturizing the skin equate with barrier repair therapy? Ann Allergy Asthma Immunol. 2018;121(6) 653–656.e2. doi: https://doi.org/10.1016/j.anai.2018.07.008
12. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32(5):657–682. doi: https://doi.org/10.1111/jdv.14891
13. Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3): 329–337. doi: https://doi.org/10.1007/s12016-016-8548-5
14. Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):26–35. doi: https://doi.org/10.1016/j.jaci.2018.11.015
15. Rippke F, Schreiner V, Doering T, Maibach HI. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus aureus. Am J Clin Dermatol. 2004;5(4):217–223. doi: https://doi.org/10.2165/00128071-200405040-00002
16. Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status. Sci Rep. 2020;10(1):2721. doi: https://doi.org/1010.1038/s41598-020-59627-7
17. Berdyshev E, Goleva E, Bronova I, et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight. 2018;3(4):e98006. doi: https://doi.org/10.1172/jci.insight.98006
18. Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017;35(3): 317–326. doi: https://doi.org/10.1016/j.det.2017.02.006
19. Stier MT, Peebles RS Jr. Innate lymphoid cells and allergic disease. Ann Allergy Asthma Immunol. 2017;119(6):480–488. doi: https://doi.org/10.1016/j.anai.2017.08.290
20. Murashkin NN, Epishev RV, Fedorov DV, et al. Sensitive Skin Syndrome in Children with Atopic Dermatitis: Pathogenesis and Management Features. Voprosy sovremennoi pediatrii — Current Pediatrics. 2019;18(4):285–293. (In Russ). doi: https://doi.org/10.15690/vsp.v18i4.2046
21. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002; 347(15):1151–1160. doi: https://doi.org/10.1056/NEJMoa021481
22. Ryffel B, Alves-Filho JC. ILC2s and basophils team up to orchestrate IL-33-induced atopic dermatitis. J Invest Dermatol. 2019;139(10): 2077–2079. doi: https://doi.org/10.1016/j.jid.2019.06.118
23. Leyva-Castillo JM, Galand C, Mashiko S, et al. ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation. J Allergy Clin Immunol. 2020;145(6):1606–1614.e4. doi: https://doi.org/10.1016/j.jaci.2020.02.026
24. Iwamoto K, Nümm TJ, Koch S, et al. Langerhans and inflammatory dendritic epidermal cells in atopic dermatitis are tolerized toward TLR2 activation. Allergy. 2018;73(11):2205–2213. doi: https://doi.org/10.1111/all.13460
25. Mack MR, Brestoff JR, Berrien-Elliott MM, et al. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Sci Transl Med. 2020;12(532):eaay1005. doi: https://doi.org/10.1126/scitranslmed.aay1005
26. Murashkin NN, Savelova AA, Ivanov RA, et al. Modern View on the Role of Epidermal Barrier in Atopic Phenotype Development in Children. Voprosy sovremennoi pediatrii — Current Pediatrics. 2019;18(5):386–392. (In Russ). doi: https://doi.org/10.15690/vsp.v18i5.2064
27. Baker BS, Ovigne JM, Powles AV, et al. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol. 2003;148(4):670–679. doi: https://doi.org/10.1046/j.1365-2133.2003.05287.x
28. Pivarcsi A, Bodai L, Rethi B, et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol. 2003;15(6):721–730. doi: https://doi.org/10.1093/intimm/dxg068
29. Mempel M, Voelcker V, Kollisch G, et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not tolllike receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol. 2003;121(6):1389–1396. doi: https://doi.org/10.1111/j.1523-1747.2003.12630.x
30. Chen K, Huang J, Gong W, et al. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol. 2007;7(10):1271–1285. doi: https://doi.org/10.1016/j.intimp.2007.05.016
31. Gao N, Kumar A, Jyot J, Yu FS. Flagellin-induced corneal antimicrobial peptide production and wound repair involve a novel NF-kappaBindependent and EGFR-dependent pathway. PLoS One. 2010;5(2): e9351. doi: https://doi.org/10.1371/journal.pone.0009351
32. Leifer CA, McConkey C, Li S, et al. Linking genetic variation in human Toll-like receptor 5 genes to the gut microbiome’s potential to cause inflammation. Immunol Lett. 2014;162(2 Pt A):3–9. doi: https://doi.org/10.1016/j.imlet.2014.07.017
33. Kondo Y, Higa-Nakamine S, Noguchi N, et al. Induction of epithelialmesenchymal transition by flagellin in cultured lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2012;303(12):L1057–L1069. doi: https://doi.org/10.1152/ajplung.00096.2012
34. Koh LF, Ong RY, Common JE. Skin microbiome of atopic dermatitis. Allergol Int. 2022;71(1):31–39. doi: https://doi.org/10.1016/j.alit.2021.11.001
35. Fyhrquist N, Muirhead G, Prast-Nielsen S, et al. Microbe-host interplay in atopic dermatitis and psoriasis. Nat Commun. 2019;10(1): 4703. doi: https://doi.org/10.1038/s41467-019-12253-y
36. Kim J, Kim BE, Ahn K, Leung DYM. Interactions between atopic dermatitis and Staphylococcus aureus infection: clinical implications. Allergy Asthma Immunol Res. 2019;11(5):593–603. doi: https://doi.org/10.4168/aair.2019.11.5.593
37. Orfali RL, Yoshikawa FSY, Oliveira LMDS, et al. Staphylococcal enterotoxins modulate the effector CD4+ T cell response by reshaping the gene expression profile in adults with atopic dermatitis. Sci Rep. 2019;9(1):13082. doi: https://doi.org/10.1038/s41598-019-49421-5
38. Orfali RL, da Silva Oliveira LM, de Lima JF, et al. Staphylococcus aureus enterotoxins modulate IL-22-secreting cells in adults with atopic dermatitis. Sci Rep. 2018;8(1):6665. doi: https://doi.org/10.1038/s41598-018-25125-0
39. Leistner R, Hanitsch LG, Krüger R, et al. Skin Infections Due to Panton-Valentine Leukocidin-Producing S. Aureus. Dtsch Arztebl Int. 2022;119(45):775–784. doi: https://doi.org/10.3238/arztebl.m2022.0308
40. Murashkin NN, Epishev RV, Materikin AI, et al. Mechanisms of Development and Variants of Therapeutic Management of Steroid Resistance in Patients with Atopic Dermatitis. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):370–375. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2309
41. Nakatsuji T, Gallo RL. The role of the skin microbiome in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(3):263–269. doi: https://doi.org/10.1016/j.anai.2018.12.003
42. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children’s hospitals in the United States. Clin Infect Dis. 2009;49(1): 65–71. doi: https://doi.org/10.1086/599348
43. Francis NA, Ridd MJ, Thomas-Jones E, et al. Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. Ann Fam Med. 2017;15(2):124–130. doi: https://doi.org/10.1370/afm.2038
44. George SM, Karanovic S, Harrison DA, et al. Interventions to reduce Staphylococcus aureus in the management of eczema. Cochrane Database Syst Rev. 2019;2019(10):CD003871. doi: https://doi.org/10.1002/14651858.CD003871.pub3
45. Harkins CP, Holden MTG, Irvine AD. Antimicrobial resistance in atopic dermatitis: need for an urgent rethink. Ann Allergy Asthma Immunol. 2019;122(3):236–240. doi: https://doi.org/10.1016/j.anai.2018.11.027
46. Alexander H, Paller AS, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2020;182(6):1331–1342. doi: https://doi.org/10.1111/bjd.18643
47. Red Book: 2018 Report of the Committee of Infectious Diseases. Kimberlin D, Brady M, Jackson M, Long S, eds. Itasca, IL: American Academy of Pediatrics; 2018.
48. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Disease Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292. doi: https://doi.org/10.1093/cid/cir034
49. Guo Y, Song G, Sun M, et al. Prevalence and Therapies of AntibioticResistance in Staphylococcus aureus. Front Cell Infect Microbiol. 2020;10:107. doi: https://doi.org/10.3389/fcimb.2020.00107
50. Rose W, Fantl M, Geriak M, et al. Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients? Clin Infect Dis. 2021;73(12):2353–2360. doi: https://doi.org/10.1093/cid/ciab452
51. Sutter DE, Milburn E, Chukwuma U, et al. Changing susceptibility of Staphylococcus aureus in a US pediatric population. Pediatrics. 2016; 137(4):e20153099. doi: https://doi.org/10.1542/peds.2015-3099
52. Rangel SM, Paller AS. Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. Clin Dermatol. 2018;36(5): 641–647. doi: https://doi.org/10.1016/j.clindermatol.2018.05.005
53. Ashbaugh AG, Kwatra SG. Atopic Dermatitis Disease Complications. Adv Exp Med Biol. 2017;1027:47–55. doi: https://doi.org/10.1007/978-3-319-64804-0_5
54. Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am. 2015;35(1):161–183. doi: https://doi.org/10.1016/j.iac.2014.09.008
55. Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1): 10–22.e2. doi: https://doi.org/10.1016/j.anai.2017.10.039
56. Woods MT, Brown PA, Baig-Lewis SF, Simpson EL. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. J Drugs Dermatol. 2011;10(2):171–176.
57. Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, et al. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. J Dtsch Dermatol Ges. 2013;11(5):437–443. doi: https://doi.org/10.1111/ddg.12074
58. Jensen JM, Weppner M, Dähnhardt-Pfeiffer S, et al. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial. Acta Derm Venereol. 2013;93(5):515–519. doi: https://doi.org/10.2340/00015555-1533
59. Hung SH, Lin YT, Chu CY, et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol. 2007;98(1):51–56. doi: https://doi.org/10.1016/S1081-1206(10)60859-9
60. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155(4):680–687. doi: https://doi.org/10.1111/j.1365-2133.2006.07410.x
61. Gonzalez ME, Schaffer JV, Orlow SJ, et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. J Am Acad Dermatol. 2016;75(3): 481–493.e853. doi: https://doi.org/10.1016/j.jaad.2016.04.066
62. Crellin NK, Garcia RV, Hadisfar O, et al. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol. 2005;175(12):8051–8059. doi: https://doi.org/10.4049/jimmunol.175.12.8051
63. Aries MF, Hernandez-Pigeon H, Vaissière C, et al. Anti-inflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models. Clin Cosmet Investig Dermatol. 2016;9:421–434. doi: https://doi.org/10.2147/CCID.S113180
64. Noizet M, Bianchi P, Galliano MF, et al. Broad spectrum repairing properties of an extract of Aquaphilus dolomiae on in vitro and ex vivo models of injured skin. J Eur Acad Dermatol Venereol. 2020;34 Suppl 5: 37–42. doi: https://doi.org/10.1111/jdv.16477
65. Martin H, Laborel-Préneron E, Fraysse F, et al. Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4+ T cell activation. Pharm Biol. 2016;54(11):2782–2785. doi: https://doi.org/10.3109/13880209.2016.1173069
66. Lee SE, Jeong SK, Lee SH. Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J. 2010;51(6):808–822. doi: https://doi.org/10.3349/ymj.2010.51.6.808
67. Nguyen T, Castex-Rizzi N, Redoules D. Immunomodulatory, antiinflammatory, anti-pruritus and tolerogenic activities induced by I-modulia, an Aquaphilus dolomiae culture extract, in atopic dermatitis pharmacology models. Ann Dermatol Venereol. 2017;144(Suppl 1): S42–S49. doi: https://doi.org/10.1016/S0151-9638(17)31042-6
68. Fostini AC, Georgescu V, Decoster CJ, Girolomoni G. A cream based on Aquaphilus dolomiae extracts alleviates non-histaminergic pruritus in humans. Eur J Dermatol. 2017;27(3):317–318. doi: https://doi.org/10.1684/ejd.2017.2994
69. Guerrero D, Mengeaud V, Verriere F, Nocera T. Efficacy and tolerabity of an association with cooper, zinc and sucralfate in dermatology. Les Nouvelles Dermatol. 2002;21(Suppl.2):20–23.
70. Schwartz JR, Marsh RG, Draelos ZD. Zinc and skin health: overview of physiology and pharmacology. Dermatol Surg. 2005;31 (7 Pt 2):837–847; discussion 847. doi: https://doi.org/10.1111/j.1524-4725.2005.31729
71. Baldwin S, Odio MR, Haines SL, et al. Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper. J Eur Acad Dermatol Venereol. 2001; 15 Suppl 1:5–11. doi: https://doi.org/10.1046/j.0926-9959. 2001.00002.x
72. Merial-Kieny C, Castex-Rizzi N, Selas B, et al. Avène Thermal Spring Water: an active component with specific properties. J Eur Acad Dermatol Venereol. 2011;25 Suppl 1:2–5. doi: https://doi.org/10.1111/j.1468-3083.2010.03892.x
73. Joly F, Charveron M, Ariès MF, et al. Effect of Avène spring water on the activation of rat mast cell by substance P or antigen. Skin Pharmacol Appl Skin Physiol. 1998;11(2):111–116. doi: https://doi.org/10.1159/000029816
74. Boisnic S, Branchet-Gumila MC, Segard C. Inhibitory effect of Avène spring water on vasoactive intestinal peptide-induced inflammation in surviving human skin. Int J Tissue React. 2001;23(3):89–95.
75. Casas C, Ginisty H, Alvarez-Georges S, et al. Molecular characterization of inflammation and Staphylococcus aureus colonization of involved skin of atopic dermatitis patients A non-invasive approach. Skin Pharmacol Physiol. 2008;21(5):260–268. doi: https://doi.org/10.1159/000143391
Review
For citations:
Epishev R.V., Materikin A.I., Opryatin L.A., Ivanov R.A., Leonova M.A., Savelova A.A. Management and Prevention of Atopic Dermatitis Infectious Complications in Children. Current Pediatrics. 2023;22(5):374-381. (In Russ.) https://doi.org/10.15690/vsp.v22i5.2638
Views:
434
Email this article 
